A deluge of generic weight-loss drugs are forecast to flow soon after when patents of semaglutide, used to make Novo's weight loss medicine, start to expire in 2026.Locally, Indias largest pharma firm Sun Pharmaceutical Industries Ltd
Growing Use in Obesity Treatment: As GLP-1 receptor agonists gain recognition as an effective treatment for obesity, the parenteral route remains the preferred method due to its efficiency in delivering the necessary dosage for weight management
The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials
That reputation has since been substantially undermined by one of the most serious regulatory enforcement records of any pharmacy
The other three treatment groups were represented approximately equally in the largest cluster, with a maximum of one animal per treatment group outside the cluster
Do You Still Need Metformin
